APLI.TO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 17:45):

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada...

Stats
Dzisiejszy wolumen	3 000.00
Średni wolumen	192 619
Kapitalizacja rynkowa	4.85M
EPS	$0 ( 2024-02-11 )
Następna data zysków	( $-0.0100 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.000
ATR14	$0 (0.00%)

APPILI THERAPEUTICS INC Korelacja

10 Najbardziej pozytywne korelacje
ISV.TO	0.832

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

APPILI THERAPEUTICS INC Finanse

Annual	2022
Przychody:	$334 177
Zysk brutto:	$327 911 (98.12 %)
EPS:	$-0.0813

FY	2022
Przychody:	$334 177
Zysk brutto:	$327 911 (98.12 %)
EPS:	$-0.0813

FY	2022
Przychody:	$1.39M
Zysk brutto:	$1.39M (100.00 %)
EPS:	$-0.380

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.240

Financial Reports:

No articles found.

APPILI THERAPEUTICS INC

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.